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population during this period. Annual costs for outpa-
tient use of mood stabilizers and antipsychotic medica-
tions increased by $168 (42%) over the study interval,
totaling $565 in 1997. However, other costs of care for
these patients decreased by $2,424 during the same pe-
riod; more than 80 percent ($2,007) of this decline was
accounted for by costs incurred for services directly asso-
ciated with receipt of a diagnosis of bipolar disorder.
CONCLUSIONS: Treatment of bipolar disorder imposes
a significant economic burden to the health care system.
The increasing availability and use of novel and more ex-
pensive mood stabilizing and antipsychotic medications
for treatment of bipolar disorder does not appear to have
resulted in an increase in the total costs of the disease.
PMH3
ALZHEIMER’S DISEASE COST OF CARE IN 
MANAGED CARE
Richards KM1, Shepherd MD1, Crismon ML1, Snyder EH2
1College of Pharmacy, University of Texas at Austin, Austin, 
TX, USA; 2Novartis Pharmaceuticals, East Hanover, NJ, USA
OBJECTIVE: The purpose of the study was to examine
formal care costs (direct medical costs) and informal care
costs (non-reimbursed caregiver time) of Alzheimer’s pa-
tients enrolled in an integrated managed care organiza-
tion (MCO). METHODS: The MCO provided medical
and prescription claims data for a one-year period for 80
patients diagnosed with Alzheimer’s disease (AD) or re-
lated dementia. Severity measurements were made at
baseline, month 6, and month 12. Caregivers provided
informal care information three times throughout the
year. RESULTS: The mean annual cost of care for these
AD patients was $36,850.94 (sd  18,356.62). There
was a mean of $26,434.12 (sd  20,239.38) for formal
care costs (71.7%), and a mean of $10,416.82 (sd 
8,962.07) for informal care costs (28.3%). Costs were
calculated for patients with mild, moderate, and severe
AD, as well as for patients who lived in the community,
in institutions, and moved from community to institu-
tion. Mean annual costs were approximately 1.8 and 1.2
times higher for severe patients than for mild and moder-
ate patients, respectively. Mean annual formal care costs
were 14.3 times higher for institutionalized patients than
for those in the community. Mean annual informal costs
were 2.2 times higher for community patients than insti-
tutionalized patients. CONCLUSIONS: Through de-
tailed cost analyses, managed care decision-makers can
be better informed about the current care being provided
for AD patients. The total annual direct medical cost was
$2.1 million for these 80 managed care patients with AD.
With the increasing prevalence of AD and the higher
costs associated with the advancement of the disease,
managed care would benefit by providing treatment that
could delay or reverse the progression of AD.
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OBJECTIVE: To describe outpatient antipsychotic medica-
tion treatment patterns and estimate the diagnosis-related
costs of care associated with treatment of schizophrenic
patients in usual care. METHODS: Use of outpatient an-
tipsychotic medications and other health services during
1997 was obtained for 1,356 patients with a diagnosis of
schizophrenia in a claims database. We evaluated the
treated prevalence of outpatient antipsychotic therapy
and continuity of medication usage, and estimated the
costs of schizophrenia care, adjusting for multiple co-
variates. RESULTS: 21.2% of patients diagnosed with
schizophrenia received no antipsychotic medication in
the outpatient setting for a minimum of 12 months after-
ward; 19.2% discontinued their initial antipsychotic
without subsequent restart of an antipsychotic during the
interval; 20.9% experienced multiple treatment episodes
of the same antipsychotic; 17.8% received multiple dif-
ferent antipsychotic medications; and 20.9% received
continuous antipsychotic medication therapy. Patients re-
ceiving multiple antipsychotics incurred significantly
higher total diagnosis-related costs (P  0.001) than pa-
tients in each of the other medication treatment groups.
The average diagnosis-related cost of care for patients re-
ceiving multiple antipsychotics was $10,585, $5,692 for
patients who discontinued monotherapy without re-
start, $5,156 for patients with continuous monotherapy,
$5,068 for patients with multiple monotherapy treatment
episodes, and $2,401 for patients not receiving medica-
tion therapy. The proportion of costs for institutional
care incurred by patients ranged from 37% for patients
receiving continuous medication monotherapy to 77%
for patients who either discontinued or never received
medication therapy. CONCLUSIONS: A substantial pro-
portion of schizophrenic patients received either no expo-
sure or limited exposure to antipsychotic medications.
Patients who received medication monotherapy either
continuously or through successive treatment episodes
were less costly than patients who received multiple med-
ication therapies or discontinued medication monother-
apy. Reductions in institutional costs among patients re-
ceiving continuous antipsychotic monotherapy offset costs
of these medications.
